Announcement of Business Collaboration Agreement

Business Collaboration Agreement
with TRANSGENIC GROUP INC. and TRANS GENIC INC.

October 7^th, 2025
Hokkaido System Science Co., Ltd.

We are pleased to announce that Hokkaido System Science Co., Ltd. (“HSS”) has entered into a business collaboration agreement today with TRANSGENIC GROUP INC. (President and CEO: Kenji Fukunaga, Fukuoka) and TRANS GENIC INC. (President and CEO: Koji Takashima, Chiyoda-ku, Tokyo; “TransGenic”).

HSS has engaged in custom synthesis over more than 30 years, and now utilizes that experience to develop a CDMO business for nucleic acid drugs, providing comprehensive total support for processes including sequence design, oligonucleotide manufacturing, and genetic analysis after administration to cells/animals.
Meanwhile, TransGenic has a system to support broadly from exploratory research to clinical tests, especially advantages over pharmacological and toxicity test using genetically modified animals.

In recent years, nucleic acid drugs have been widely developed by academia researchers and major pharmaceutical companies, and there is a demand for fast and low-cost support for obtaining proof of concept, such as small-scale synthesis and screening-level evaluation of efficacy and toxicity. In addition, at the stage of regulatory affairs such as clinical trial applications, a far-sighted system is also required to take into account of analytical method validation and design/implementation of GLP-compliant studies.

By combining the strengths of both companies, nucleic acid drug manufacturing technology and an evaluation system using animal models, we will consistently provide high-quality and high-value-added development support, and contribute to accelerate the research and development of nucleic acid drugs as well as the practical application of pharmaceuticals.

For any inquiries:
Hokkaido System Science Co., Ltd.
TEL：011-768-5901　E-mail：kikaku@hssnet.co.jp